This study aimed to evaluate the changes in the VOR gain after intratympanic gentamicin therapy and to correlate them with the mid-term effects on the control of vertigo, in a population of Menière's disease patients.
The study design was a prospective “Outcomes research.”
Tertiary referral center.
This study included 20 patients with unilateral Menière's disease refractory to medical therapy for at least 1 year, and treated with an on demand intratympanic gentamicin protocol.
Main Outcome Measure: Audiometry, caloric testing, and a vHIT before beginning the protocol were performed. Patients underwent weekly vHIT assessments until a significant gain reduction was observed. Subsequently we performed vHIT tests 1 month after the therapy completion, and then every 3 months for at least 1 year.
Complete vertigo control (class A) was achieved in 14 patients at the 12-month follow-up assessment. We observed a significant reduction in VOR gain values at the 3-week follow-up assessment. We found a significant correlation between the 1-month posttreatment ipsilateral hVOR gain and the rate of vertigo recurrence after the first IT gentamicin treatment (p = 0.012; r2 = 0.400). At the mid-term assessment, 10 patients exhibited a significant partial recovery of the hVOR gain.
The delayed effect of intratympanic gentamicin and the subsequent gain restoration are factors that may influence the patients’ outcome. The feasibility of the vHIT system makes it a useful tool to monitorize the VOR changes.
*Department of Otolaryngology, University Hospital of Getafe
†Department of Otolaryngology, Clinica Universidad de Navarra, Madrid, Spain
Address correspondence and reprint requests to Eduardo Martin-Sanz, Ph.D., M.D., Department of Otolaryngologly, Hospital Universitario de Getafe, Autovía de Toledo, km 12,500, 28905 Getafe, Madrid, Spain; E-mail: email@example.com
The authors disclose no conflicts of interest.